These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11705936)

  • 1. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides.
    Breukels MA; Zandvoort A; van Den Dobbelsteen GP; van Den Muijsenberg A; Lodewijk ME; Beurret M; Klok PA; Timens W; Rijkers GT
    Infect Immun; 2001 Dec; 69(12):7583-7. PubMed ID: 11705936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines.
    Breukels MA; Zandvoort A; Rijkers GT; Lodewijk ME; Klok PA; Harms G; Timens W
    Scand J Immunol; 2005 Apr; 61(4):322-8. PubMed ID: 15853914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.
    Landgren O; Björkholm M; Konradsen HB; Söderqvist M; Nilsson B; Gustavsson A; Axdorph U; Kalin M; Grimfors G
    J Intern Med; 2004 Jun; 255(6):664-73. PubMed ID: 15147530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants.
    Väkeväinen M; Eklund C; Eskola J; Käyhty H
    J Infect Dis; 2001 Sep; 184(6):789-93. PubMed ID: 11517443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal 13-valent conjugate vaccine administration after inferior response to pneumococcal vaccine.
    Gupta R; Wong CS; Fonacier L
    Allergy Asthma Proc; 2017 Sep; 38(5):365-369. PubMed ID: 28814356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: tailoring better vaccination strategies.
    Rosado MM; Gesualdo F; Marcellini V; Di Sabatino A; Corazza GR; Smacchia MP; Nobili B; Baronci C; Russo L; Rossi F; Vito RD; Nicolosi L; Inserra A; Locatelli F; Tozzi AE; Carsetti R
    Eur J Immunol; 2013 Oct; 43(10):2659-70. PubMed ID: 23813052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compared effectiveness of the 7-valent pneumococcal conjugate vaccine in children with the 13-valent vaccine in adults.
    Gaillat J
    Med Mal Infect; 2013 Jun; 43(6):215-21. PubMed ID: 23769155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antibody response after immunization with pneumococcal polysaccharide vaccine in splenectomized mice: the effect of re-immunization with pneumococcal antigens.
    Aaberge IS; Løvik M
    APMIS; 1996 Apr; 104(4):307-17. PubMed ID: 8645471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
    Gadzinowski J; Albrecht P; Hasiec B; Konior R; Dziduch J; Witor A; Mellelieu T; Tansey SP; Jones T; Sarkozy D; Emini EA; Gruber WC; Scott DA
    Vaccine; 2011 Apr; 29(16):2947-55. PubMed ID: 21335032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of pneumococcal polysaccharide vaccines: no simple answers.
    French N
    J Infect; 2003 Feb; 46(2):78-86. PubMed ID: 12634068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
    Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
    Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.